Background-Vascular injury and atherothrombosis involve vessel infiltration by inflammatory leukocytes, migration of medial vascular smooth muscle cells to the intimal layer, and ultimately acute thrombosis. A strategy to simultaneously target these pathological processes has yet to be identified. The secreted protein, Slit2, and its transmembrane receptor, Robo-1, repel neuronal migration in the developing central nervous system. More recently, it has been appreciated that Slit2 impairs chemotaxis of leukocytes and vascular smooth muscle cells toward diverse inflammatory attractants. The effects of Slit2 on platelet function and thrombus formation have never been explored. Methods and Results-We detected Robo-1 expression in human and murine platelets and megakaryocytes and confirmed its presence via immunofluorescence microscopy and flow cytometry. In both static and shear microfluidic assays, Slit2 impaired platelet adhesion and spreading on diverse extracellular matrix substrates by suppressing activation of Akt. Slit2 also prevented platelet activation on exposure to ADP. In in vivo studies, Slit2 prolonged bleeding times in murine tail bleeding assays. Using intravital microscopy, we found that after mesenteric arteriolar and carotid artery injury, Slit2 delayed vessel occlusion time and prevented the stable formation of occlusive arteriolar thrombi. Conclusions-These data demonstrate that Slit2 is a powerful negative regulator of platelet function and thrombus formation. The ability to simultaneously block multiple events in vascular injury may allow Slit2 to effectively prevent and treat thrombotic disorders such as myocardial infarction and stroke. (Circulation. 2012;126:1385-1395.)
C ardiovascular disease leading to heart attack and stroke remains the leading cause of mortality and morbidity in the Western world. 1, 2 Atherosclerosis is a progressive disease characterized by accumulation of inflammatory cells and vascular smooth muscle cells (VSMCs) within the intima of injured blood vessels. The atherosclerotic plaque is made up of immune cells, including monocytes, macrophages, neutrophils, T lymphocytes, and VSMCs, that migrate from the media to the intima where they proliferate and secrete extracellular matrix proteins. Platelets have also been implicated in the initiation of atherosclerotic lesion formation. 3, 4 These events result in progressive narrowing of the vessel, allowing platelet aggregation and activation to ultimately form vascular occlusive thrombi, precipitating acute coronary syndromes and ischemic stroke. 5 
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Strategies that block recruitment to the intima of immune cells and VSMCs are partially protective against vascular injury in both animal models and human patients. Inhibiting monocyte and VSMC recruitment to selected chemoattractants partially prevents atherosclerosis and its clinical manifestations, and simultaneous blockade of 2 chemotactic pathways confers additional, but not complete, benefit. 2, 6 Medical therapies that inhibit platelet activation and aggregation are a mainstay of treatment for patients at risk for cardiovascular events, making antiplatelet agents the most widely prescribed drugs worldwide. 1 However, these agents also provide only partial protection against cardiovascular events.
Given the variety of infiltrating cell types and molecular migration cues involved in atherogenesis, it is unlikely that targeting a single chemoattractant pathway will achieve widespread clinical success. Rather, generalized blockade of harmful cell migration cues, combined with platelet inhibition within the vasculature, would be more beneficial.
The Slit family of secreted proteins, together with their transmembrane receptor, Roundabout (Robo), act as repellents for migrating neurons and axons during the development of the central nervous system. [7] [8] [9] It has recently been appreciated that Slit and Robo are also expressed in mature organisms, and an isoform of Robo, Robo-1, has been detected on the surface of several cell types involved in vascular injury and atherogenesis, including VSMCs, neutrophils, and mononuclear leukocytes. 10 -14 Work from our group and others has shown that Slit2 interacts with Robo-1 to prevent directional migration of these cells in response to diverse inflammatory chemoattractant cues both in vitro and in vivo. 10 -15 The possible role of Slit2 in modulating platelet recruitment and activation has heretofore not been explored. We report here that Robo-1 is expressed in megakaryocytes and platelets and is present on the platelet cell surface in humans and mice. We further demonstrate that Slit2 is a potent inhibitor of platelet adhesion, spreading, and activation in response to diverse stimuli in vitro and impairs platelet function and thrombus stability in vivo. These results suggest that Slit2, a naturally occurring protein, has the potential to serve as a therapeutic agent for simultaneously inhibiting the development of atherosclerotic vascular lesions and the acute platelet thrombus that collectively contribute to heart attack and stroke.
Methods
Detailed methods are available in the online-only Data Supplement.
Isolation of Human and Murine Platelets
Human washed platelets were isolated from whole blood collected from healthy volunteers into acid citrate dextrose (1 vol). Murine platelets were isolated from blood collected by cardiac puncture in hirudin.
Statistical Analysis
ANOVA was performed to compare group means in multiple comparisons. In other cases, the Student 2-tailed t test was used for comparison of means, or the Fisher exact test was used for comparison of proportions. Values of PϽ0.05 were considered significant.
Results

Platelets Express Robo-1 on Their Surface
Immunoblot analysis of cell lysates detected expression of the Slit2 receptor, Robo-1, in human platelets and their precursor megakaryocytes ( Figure 1A ). Laser immunofluorescence confocal microscopy showed that in human and murine platelets, Robo-1 receptors localized to the cell surface ( Figure 1B and 1C) . Using flow cytometry, we observed that 96% of human platelets expressed Robo-1 ( Figure 1D and 1E ).
Because the repulsive effects of Slit2 are thought to be mediated by the leucine-rich regions present at the N-terminus, we next examined the binding of a truncated N-terminal preparation of Slit2 (Slit2-N) comprising these leucine-rich regions to the platelet surface. 10, 16 Using flow cytometry, we directly demonstrated binding of Slit2-N to Robo-1 on the surface of platelets ( Figure IA , IB, and IH in the online-only Data Supplement). To verify that the observed binding of Slit2 was specific, we generated a soluble N-terminal fragment of Robo-1 (RoboN) that binds Slit2, competitively preventing binding of Slit2 to Robo-1 on the cell surface, thereby preventing initiation of downstream signaling events. 17 Using flow cytometry, we demonstrated that RoboN inhibited binding of Slit2-N to the surface of platelets in a dose-dependent manner (Figure IB-IF and IH in the online-only Data Supplement). To further verify that the observed effects of Slit2 were not due to nonspecific protein binding, we generated mutant Slit2 protein that lacks the second leucine-rich region that is necessary for binding to Robo-1 (Slit⌬D2). 16, 18 Flow cytometry analysis demonstrated that this mutant Slit2 protein, Slit⌬D2, did not significantly bind to the surface of platelets ( Figure IG and IH in the online-only Data Supplement). Furthermore, activation of platelets with the agonist ADP did not significantly alter the binding of Slit2 to the surface of platelets ( Figure II and IJ in the online-only Data Supplement). Together, these data demonstrate that human and mouse platelets express Robo-1 and that Slit2 directly binds Robo-1 receptors on the platelet surface.
Slit2 Inhibits Spreading of Human Platelets
The potential effects of Slit2/Robo-1 interactions on platelet function were first examined by assessing the effects of Slit2 on adhesion and spreading of human platelets on a fibrinogen-coated surface. Untreated cells progressively spread on fibrinogen-coated coverslips during a 30-minute observation period (Figure 2A and 2B ). In the presence of Slit2, platelet spreading was markedly decreased, with cells exhibiting short, warped filopodia and decreased formation of lamellar sheets (Figure 2A ). After 30 minutes, the mean platelet surface area was 20.9Ϯ2.5 m 2 in the presence of Slit2, significantly less than the 33.4Ϯ0.6-m 2 mean surface area observed for untreated cells (PϽ0.05; Figure 2B ). In real-time visualization, when Slit2 was not present, platelets demonstrated smooth, fluid formation of filopodia and lamellipodia (Video I in the online-only Data Supplement). In sharp contrast, Slit2-treated platelets exhibited rounding of the cell body and development of dynamic and motile filopodial structures but limited formation of lamellar sheets between the filopodia (Video II in the online-only Data Supplement).
To determine whether Slit2 selectively inhibits fibrinogeninduced platelet spreading, the effects of Slit2 on platelet spreading on fibronectin and collagen were examined as described above. After 30 minutes, the mean surface area of platelets on fibronectin-coated coverslips was 19 Figure 2C and 2D). On collagencoated coverslips, the mean surface area was 13.5Ϯ0.7 m in the presence of Slit2, significantly less than that of untreated cells (20.8Ϯ1.9 m 2 ; PϽ0.05; Figure 2E and 2F). We next tested whether Slit2-N similarly inhibited platelet spreading. 10, 16 After 30 minutes, the mean platelet surface area on fibrinogen-coated surfaces was 23.3Ϯ0.7 m 2 in the presence of Slit2-N, significantly less than the 36.1Ϯ0.6-m 2 mean surface area observed for untreated cells (PϽ0.01; Figure IIA and IIB in the online-only Data Supplement). To verify that the observed effects of Slit2 were not due to nonspecific protein binding, we also tested platelet spreading with Slit⌬D2. In the presence of Slit⌬D2, platelet spreading on fibrinogen was unimpaired ( Figure IIA Collectively, these results demonstrate that Slit2 specifically inhibits platelet adhesion and spreading on diverse substrates.
Slit2 Inhibits Platelet Adhesion Under Shear Flow Conditions
Collagen is the first potentially activating substrate that platelets typically encounter within an injured blood vessel, and their response is sensitive to shear flow conditions. We used Bioflux microfluidic channels coated with collagen to mimic the hydrodynamic flow conditions that would be encountered by platelets within the arterial circulation. 19 For untreated cells, the average surface area covered by platelets after 4 minutes was 8.3Ϯ1.3% at a shear flow rate of 1000 seconds Ϫ1 ( Figure 3A and 3B). For cells treated with Slit2, this area markedly decreased to 1.3Ϯ0.5% (PϽ0.01; Figure  3A and 3B). At a shear flow rate of 1900 seconds Ϫ1 , comparable to hydrodynamic conditions encountered within large arteries, the average platelet surface area coverage decreased 4-fold from 12.0Ϯ2.4% to 3.1Ϯ0.9% on exposure to Slit2 (PϽ0.05; Figure 3A and 3C and Videos III and IV in the online-only Data Supplement). In the presence of Slit2-N, we observed a decrease in platelet adhesion comparable to that seen with full-length Slit2 protein (control, 8.7Ϯ1.4% versus Slit2-N, 2.5Ϯ0.5%; Figure IIIA and IIIB in the online-only Data Supplement; PϽ0.05). To verify the specificity of Slit2-induced responses, we incubated platelets with Slit⌬D2, which lacks the Robo-1-binding domain. Platelet adhesion was no different in the presence of Slit⌬D2 than control platelets but was significantly higher than adhesion of platelets treated with Slit2-N (control, 8.7Ϯ1.4%; Slit2-N, 2.5Ϯ0.5%; Slit⌬D2, 9.2Ϯ1.9%; Slit⌬D2 versus Slit2-N, PϽ0.05; Figure IIIA and IIIB in the online-only Data Supplement). Taken together, these data demonstrate that Slit2 specifically inhibits platelet adhesion under shear flow conditions.
Slit2 Does Not Affect Rac1 and Cdc42 Activation During Platelet Spreading
Slit2 has been shown to prevent chemotactic migration of various cell types by preventing activation of the Rho-family GTPases, Cdc42, and Rac. 10, 12, 13, 15 To determine whether Slit2 inhibits platelet adhesion and spreading in a similar manner, we used glutathione-S-transferase beads conjugated to the p21-binding domain of PAK1 to detect the activated GTP-bound species of Cdc42 and Rac. 13 Because the predominant isoform of Rac in human platelets is Rac1, we specifically studied the effects of Slit2 on Rac1 activation. 20 Unstimulated platelets exhibited low basal levels of activated Rac1 and Cdc42 ( Figure 4A and 4B) , and as expected, platelet spreading on fibrinogen increased the levels of
Control Slit2 Figure 2. Slit2 inhibits human platelet spreading on diverse substrates. Isolated human platelets (10 7 per 1 mL) were preincubated with Slit2 (4.5 g/mL) or an equal volume of PBS (control) for 10 minutes at 37°C and dispensed onto coverslips precoated with fibrinogen (A and B), fibronectin (C and D), or collagen (E and F) for the indicated times. A, Platelets adherent to fibrinogen were fixed, permeabilized, incubated with Alexa Fluor 488 -conjugated phalloidin, and visualized with a Leica DMIRE2 spinning-disk confocal microscope. Scale barsϭ11 m. B, Experiments were performed as in A. Images were acquired from 15 random fields, and the surface area of platelets was quantified with Volocity software. Data are expressed as meanϮSEM from 3 to 5 independent experiments. C, Experiments were performed as in A using coverslips coated with fibronectin. D, Experiments were performed as in C and quantification was done as described in B. Data are expressed as meanϮSEM from 3 to 5 independent experiments. E, Experiments were performed as in A using coverslips coated with collagen. F, Experiments were performed as in E and quantification was done as described in B. Data are expressed as meanϮSEM from 3 to 5 independent experiments. *PϽ0.05. Adhesion of platelets also involves activation of several major kinase pathways, namely p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and Akt. [21] [22] [23] [24] [25] As expected, platelet spreading on fibrinogen resulted in a significant increase in phosphorylation of p38 MAPK, ERK, and Akt (p38 MAPK: fibrinogen, 1.68Ϯ0. 39 Figure 4C and 4E). Slit2 treatment had no effect on the basal level of kinase activation (p38 MAPK: control, 0.52Ϯ0.12 AU versus Slit2, 0.48Ϯ0.12 AU; ERK: control, 0.18Ϯ0.02 AU versus Slit2, 0.29Ϯ0.11 AU; Akt: control, 0.13Ϯ0.03 AU versus Slit2, 0.14Ϯ0.04 AU; Figure 4C and 4E). Slit2 had no effect on phosphorylation of p38 MAPK or ERK (p38 MAPK: control, 1.68Ϯ0.39 AU versus Slit2, 1.25Ϯ0.34 AU; ERK: control, 0.76Ϯ0.16 AU versus, Slit2 0.56Ϯ0.12 AU; Figure 4C and 4D). In contrast, Slit2 significantly inhibited activation of Akt (control, 1.06Ϯ0.32 AU versus Slit2, 0.34Ϯ0.07 AU; PϽ0.05; Figure 4E ).
Because activation of Akt is a key event in platelet secretion of ␣-granules, we next tested the effects of Slit2 on this process. 21, 25, 26 We found that during platelet activation with ADP, Slit2 inhibited translocation of CD62P to the platelet surface (PϽ0.05; Figure IV in the online-only Data Supplement). Collectively, these data suggest that Slit2 inhibits platelet spreading by suppressing activation of Akt and furthermore that Slit2 prevents platelet activation and release of ␣-granule contents.
Slit2 Prolongs Bleeding Time In Vivo
We have observed that Slit2 inhibits platelet adhesion, spreading, and activation in vitro. To determine the possible effects of Slit2 on platelet function in vivo, we used the well-described murine tail bleeding model. After intravenous administration of vehicle to CD1 mice, bleeding time was 24.3Ϯ2.7 seconds ( Figure 5A ). After administration of Slit2 at doses of 1 and 1.8 g per mouse, the bleeding time was significantly prolonged to 61.5Ϯ9.5 and 69.8Ϯ8.9 seconds, respectively (1 g Slit2, PϽ0.05 versus vehicle; 1.8 g Slit2, PϽ0.01 versus vehicle). To verify these observations, the hemoglobin content of the saline into which the amputated tails were immersed was quantified by measuring absorbance at 575 nm. After administration of vehicle, the absorbance was 0.12Ϯ0.01 ( Figure 5B ) and rose to 0.20Ϯ0.01 (PϽ0.01 versus vehicle; Figure 5B ) for 1.0 g Slit2 and to 0.22Ϯ0.02 (PϽ0.01 versus vehicle; Figure 5B ) for 1.8 g Slit2. Administration of Slit2-N prolonged bleeding time in a dosedependent manner, with bleeding time prolonged by 10-fold at the highest dose of Slit2-N administered (vehicle, 27.6Ϯ6.5 seconds versus Slit2, 1.8 g 274.5Ϯ76.9 seconds; PϽ0.01; Figure 5C ). When administered to mice of a different strain, namely C57BL/6, Slit2-N also prolonged 
Slit2 Inhibits In Vivo Formation of Stable, Occlusive Thrombi After Vascular Injury
To test the effects of Slit2 in a more clinically relevant context, namely in acute thrombosis, we used wellestablished murine models of mesenteric arteriole thrombosis and carotid artery thrombosis. 27, 28 After administration of vehicle, we performed intravital microscopy of mesenteric arterioles in mice and saw that single platelets deposited on the injured site of the vessel wall, forming multiple visible platelet aggregates and visible thrombi after several minutes of injury ( Figure 6A ). In Slit2-N-treated mice, a trend toward prolongation of vessel occlusion time was observed compared with vehicle-treated mice (vehicle, 19.5Ϯ1.5 minutes versus Slit2, 28.1Ϯ3.6 minutes; Pϭ0.051; Figure 6A and 6B). In all vehicle-treated mice, the thrombi initially formed grew continuously to completely occlude the injured vessel ( Figure 6A A through E, Washed human platelets were preincubated with Slit2 (4.5 g/mL) or an equal volume of PBS (control) for 10 minutes at 37°C and allowed to spread on fibrinogen-coated wells for 30 minutes. Wells were washed with PBS to remove nonadherent platelets, and cell lysates were harvested from adherent platelets. A, Cell lysates were incubated with glutathione-Stransferase-p21-binding domain (GST-PBD) glutathione beads to immunoprecipitate activated Rac1, and immunoblotting was performed with anti-Rac1 antibody. Bottom, Band intensities of GTP-Rac1 normalized to total Rac1 expressed as meanϮSEM from 5 independent experiments. B, Cell lysates were incubated with GST-PBD glutathione beads to immunoprecipitate activated Cdc42, and immunoblotting was performed with anti-Cdc42 antibody. Bottom, Band intensities of GTP-Cdc42 normalized to total Cdc42 expressed as meanϮSEM from 6 independent experiments. C, Immunoblotting was performed with anti-phospho (p)-p38 MAPK antibody. Blots were stripped and reprobed with antibody detecting total p38 MAPK. Bottom, Band intensities of p-p38 MAPK normalized to total p38 MAPK expressed as meanϮSEM from 7 independent experiments. D, Experiments were performed as in C with anti-p-ERK and antitotal ERK antibodies. MeanϮSEM from 8 independent experiments. E, Experiments were performed as in C with anti-p-Akt and antitotal Akt antibodies. MeanϮSEM from 4 independent experiments. *PϽ0.05; **PϽ0.01.
was observed during growth of the thrombi ( Figure 6C ). In contrast, after administration of Slit2-N, 5 of 7 mice formed thrombi that occluded the vessel and quickly dissociated, resulting in release of downstream emboli (vehicle, 5Ϯ1 versus Slit2, 26Ϯ5; PϽ0.005; Figure 6C and Video V in the online-only Data Supplement) and partial reopening of occluded arterioles ( Figure 6A and 6D and Video V in the online-only Data Supplement). In the remaining 2 Slit2-Ntreated mice, thrombus formation was observed but complete vessel occlusion never occurred. At the end of the observation period (40 minutes), vessels remained partially open in none of the vehicle-treated mice but in all of the Slit2-N-treated mice (PϽ0.05; Figure 6D ).
We next tested the effects of Slit2 in a model that more closely mimics acute stroke in humans, namely carotid artery thrombosis. Once again, Slit2-treated mice exhibited a significant delay in vessel occlusion times compared with the group treated with Slit⌬D2 (Slit2-N, 14.0Ϯ1.3 minutes versus Slit⌬D2, 10.6Ϯ0.6 minutes; PϽ0.05; Figure 6E ). Collectively, these data demonstrate that Slit2 specifically prevents the formation of stable, occlusive arteriolar thrombi.
Discussion
The soluble protein Slit2, interacting with its transmembrane receptor Robo-1, was first described in Drosophila as a neuronal and axonal repellent during development of the central nervous system. [7] [8] [9] Since then, Slit2 has been shown to inhibit chemotaxis of leukocytes and VSMCs toward a number of attractant cues associated with critical events in the progression of vascular lesions. 10, [12] [13] [14] [15] However, the effect of Slit2 on platelet functions has previously been unexplored. In this study, we demonstrate the unexpected ability of Slit2/ Robo-1 interactions to inhibit several aspects of platelet adhesion, activation, and thrombus formation in vitro and in vivo. The antithrombotic properties of Slit2 point to its use as a potent agent capable of simultaneously preventing the vascular inflammation, neointimal proliferation, and thrombus formation that collectively result in occlusion of diseased vessels.
Although neuronal guidance cues belonging to the semaphorin and ephrin families have been implicated in leukocyte migration and platelet function, their precise role is unclear. Indeed, ephrins and semaphorins have been reported to both enhance and inhibit inflammation and platelet function. 29 -31 Work from our group and others demonstrates that Slit2 inhibits inflammatory cell and VSMC recruitment both in vitro and in vivo. 10, [12] [13] [14] [15] Although Slit2 inhibits chemotactic migration of leukocytes and VSMCs, the underlying mechanisms are not well understood. We recently showed that Slit2 inhibits polarization of migrating cells by preventing activation-induced generation of actin filament free barbed ends, necessary for rapid actin polymerization at the leading edge of the cell. 13, 32 These data are in keeping with observations from neuronal cells connecting Robo-1 to cytoskeletal proteins, including Slit-Robo GTPase-activating protein-1 and Ena. 33, 34 Platelet adhesion and spreading also involve cytoskeletal stabilization and destabilization. Accordingly, we found that Slit2 inhibited platelet spreading on diverse substrates, including fibrinogen, fibronectin, and collagen. Because Slit2 is a large glycoprotein, we considered the possibility that it may directly bind to glycoprotein 1b␣, the receptor for von Willebrand factor, on the surface of platelets, thereby blocking steric interactions between glycoprotein 1b␣ and von Willebrand factor. 35 To examine this possibility, we tested the effects of Slit2 on platelet Platelet adhesion and spreading depend on rapid phospholipid metabolism and activation of major kinase pathways, especially Akt, ERK, and p38 MAPK. We found that Slit2 did not inhibit activation of ERK or p38 MAPK during platelet spreading. Our results are supported by observations of human neutrophils, human granulocytic cells, and Jurkat T lymphocytes, in which Slit2 did not affect chemoattractantinduced activation of ERK or p38 MAPK. 13, 14 In yet another study, Slit2 suppressed ERK activation in chemokinestimulated breast cancer cells. 11 Akt is a well-recognized downstream effector of phosphatidylinositol 3-kinase and has been shown to phosphorylate and activate glycoprotein IIb/IIIa, thereby regulating actin assembly and promoting platelet shape change and stable aggregation. 21, 25, 26, 36, 37 Accordingly, we found that Slit2 inhibited Akt activation during platelet adhesion and spreading. These results are in concordance with those of others, demonstrating that Slit2 suppresses activation of Akt in Jurkat T lymphocytes after chemokine stimulation. 12 Interestingly, Akt-deficient platelets have a defect in secretion that results in reduced fibrinogen binding and consequently impaired aggregation. 25 The differential effects of Slit2 on inducible kinase activity can be attributed to the different cell types used. Previous reports have involved stimulating cells with chemoattractants in solution, whereas our study focused on deciphering how Slit2 modulates signaling pathways during platelet adhesion and spreading on immobilized ligands. Our studies indicate that Slit2 may suppress platelet spreading in part by downregulating Akt activation by limiting integrin function.
Our studies further demonstrated that during platelet adhesion and spreading, activation of the small Rho-family GTPase, Cdc42, was not affected by Slit2. These data differ from studies in human neutrophils and brain tumor cells in which Slit2 inhibited cell migration by preventing activation of Cdc42. 13, 17, 34, 38 In another report involving VSMCs, Slit2 inhibited cell chemotaxis but did not prevent Cdc42 activation. 10, 12 We found that the formation of dynamic, motile platelet filopodia was unaffected by Slit2. These results are entirely in keeping with observations in platelets derived from Cdc42-deficient mice. In platelets lacking Cdc42, spreading on fibrinogen and filopodial formation are completely intact. 39 Using time-lapse videomicroscopy, we observed that Slit2 inhibited formation of lamellipodia during platelet adhesion and spreading. These effects are reminiscent of Rac1 deficiency. Indeed, platelets from Rac1-deficient mice display impaired lamellipodia formation and spreading on collagen but retain the ability to form filopodia. 20 Surprisingly, we did not find that Slit2 inhibited activation of Rac1 during platelet spreading. Emerging evidence points to Rac1 acting upstream of phosphatidylinositol 3-kinase and hence Akt during platelet activation. 40 -42 Thus, it is possible that Rac1 activation occurred acutely and transiently in early stages of platelet adhesion and spreading. Additionally, secondary platelet agonist receptors such as those of P2Y 12 and thromboxane A 2 are known to activate phospholipase C and downstream signaling pathways that activate Rac1. 43 Thus, the positive feedback loop and ambiguity in multiple signaling pathways generated by secondary platelet mediators may have masked the effects of Slit2 ( Figure VII in the online-only Data Supplement).
We found that during ADP-mediated activation, Slit2 inhibited CD62P translocation to the surface of human platelets. These results are in keeping with work from other groups identifying a central role for Akt in platelet granular secretion. 21, 25, 26 Our findings are also in agreement with a recent study showing that Cdc42 is not required for ␣-granule secretion. 39 An intriguing question is how soluble levels of Slit2 vary in health and disease, particularly in the setting of cardiovascular disease. At a whole-organ level, Slit2 production has been demonstrated in brain, kidney, lung, and heart. 14 Cell types that have been shown to produce Slit2 include arterial endothelial cells, VSMCs, and fibroblasts. 10, 14 Perusal of the Plasma Proteome Database (http://www.plasmaproteomedata base.org/index.html) indicates that both Slit2 and Robo-1 have been detected in human plasma. However, the regulation of the physiological secretion of Slit2 has yet to be explored. Future studies examining the levels of Slit2 and Robo-1 in healthy subjects and in patients with cardiovascular disease will help to elucidate the mechanisms by which these proteins influence atherogenesis.
Of greatest significance, using well-established mouse models of tail bleeding, mesenteric arteriole thrombosis, and carotid artery thrombosis, we found that Slit2 impairs platelet function in vivo. Specifically, we found that administration of exogenous Slit2 impairs hemostasis and prevents formation of occlusive, stable thrombi in blood vessels subjected to acute injury. These findings point to the use of Slit2 as a potent new antiplatelet therapy to prevent the formation of thrombi that ultimately occlude vessels and cause myocardial or cerebral ischemia and infarction. 1,2 Our findings are even more compelling when one considers the distinct roles played by leukocytes, VSMCs, and platelets in initiating and exacerbating vascular injury and atherosclerosis. 1, 2 Given the variety of cells, responses, and molecular cues involved in acute vascular injury and atherothrombosis, it is unlikely that targeting a single pathological pathway such as leukocyte infiltration or platelet activation will provide comprehensive clinical benefit. Until now, a single therapy that simultaneously blocks the different pathological processes that cause vascular injury has proven elusive. We report here that Slit2 inhibits platelet adhesion, spreading, and activation, and previous reports have demonstrated that the same protein inhibits leukocyte recruitment and chemotactic VSMC migration. 10, [12] [13] [14] [15] These observations make Slit2 an exciting therapeutic candidate for the prevention and treatment of atherothrombosis and acute vascular injury.
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